# **Product** Data Sheet

# Linalool-d<sub>3</sub>

Cat. No.: HY-N0368S CAS No.: 1216673-02-7 Molecular Formula:  $C_{10}H_{15}D_3O$ Molecular Weight: 157.27

Target: Apoptosis; iGluR; Endogenous Metabolite

Pathway: Apoptosis; Membrane Transporter/Ion Channel; Neuronal Signaling; Metabolic

Enzyme/Protease

Storage: Pure form -20°C 3 years

4°C 2 years -80°C 6 months

In solvent -20°C 1 month

#### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (635.85 mM; Need ultrasonic)

| Preparing<br>Stock Solutions | Solvent Mass<br>Concentration | 1 mg      | 5 mg       | 10 mg      |
|------------------------------|-------------------------------|-----------|------------|------------|
|                              | 1 mM                          | 6.3585 mL | 31.7925 mL | 63.5849 mL |
|                              | 5 mM                          | 1.2717 mL | 6.3585 mL  | 12.7170 mL |
|                              | 10 mM                         | 0.6358 mL | 3.1792 mL  | 6.3585 mL  |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (15.90 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (15.90 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (15.90 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description Linalool- $d_3$  is the deuterium labeled Linalool[1]. Linalool is natural monoterpene in essential olis of coriander, acts as a competitive antagonist of Nmethyl d-aspartate (NMDA) receptor, with anti-tumor, anti-cardiotoxicity activity[2].Linalool is a PPARα ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome[3]. In Vitro Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as

Page 1 of 2 www.MedChemExpress.com

tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to

## affect the pharmacokinetic and metabolic profiles of drugs[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **REFERENCES**

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
- [2]. Oner Z1, et al. The protective and therapeutic effects of linalool against doxorubicin-induced cardiotoxicity in Wistar albino rats. Hum Exp Toxicol. 2019 Apr 12:960327119842634.
- [3]. Jun HJ, et al. Linalool is a PPAR $\alpha$  ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome. J Lipid Res. 2014 Jun55(6):1098-110.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com